World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 10 February 2025
Main ID:  NCT03110315
Date of registration: 28/03/2017
Prospective Registration: Yes
Primary sponsor: Theodore R. Brown, MD MPH
Public title: A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia DREAM
Scientific title: A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Date of first enrolment: March 28, 2017
Target sample size: 36
Recruitment status: Completed
URL:  https://clinicaltrials.gov/ct2/show/NCT03110315
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 4
Countries of recruitment
United States
Contacts
Name:     Theodore R Brown, MD, MPH
Address: 
Telephone:
Email:
Affiliation:  EvergreenHealth Multiple Sclerosis Center
Key inclusion & exclusion criteria
Inclusion Criteria:

- Diagnosis of multiple sclerosis made at least 3 months prior based on McDonald
criteria;

- Age 18-75 inclusive;

- Expanded Disability Status Scale (EDSS) 0- 7.5;

- Clinical stability defined as no multiple sclerosis exacerbation or change in
disease modifying therapy for 60 days prior to screening;

- Screening Fatigue Severity Scale score of =4.0;

- Has Insomnia Disorder defined by diagnostic criteria published in the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition (DSM-5); namely, subject report
of all of the following:

- One of the following: difficulty initiating sleep; difficulty maintaining
sleep; or early morning waking;

- Sleep disturbance causes clinically significant distress or impairment in
social, occupational, educational, academic, behavioral, or other important
areas of functioning;

- Sleep difficulty has occurred on 3 or more nights per week;

- Sleep difficulty has been present for at least the past 3 months;

- Sleep difficulty occurs despite adequate opportunity for sleep;

- Insomnia is not explained by another sleep disorder;

- Insomnia is not attributable to physiological effects of a consumed substance;

- May use other medications that could influence sleep, other than those specifically
prohibited, as long as the dose is stable for 4 weeks preceding screening, with no
dose changes during the study;

- Signed and dated Institutional Review Board-approved informed consent form before
any protocol-specific screening procedures have been performed.

Exclusion Criteria:

- Use of potential multiple sclerosis-associated fatigue drugs within 3 days of
screening until study completion, including modafinil, armodafinil, amantadine,
methylphenidate, products with amphetamine or dextroamphetamine;

- Use of any of any prohibited medication (including Digoxin, benzodiazepines,
barbiturates, opiates, Zolpidem, Zaleplon, Eszopiclone, moderate or strong CYP3A
inhibitors, or strong inducers of CYP3A) from 3 days prior to screening to
termination visit;

- Female who is breast-feeding, pregnant, or has the potential to become pregnant
during the course of the study (fertile and unwilling/unable to use effective
contraceptive measures);

- History of narcolepsy;

- Has a diagnosis of severe chronic obstructive pulmonary disease (COPD), defined by
forced expiratory volume 1 (FEV1) < 50% of predicted on most recent available
pulmonary function test (PFT). Pulmonary function test is not required if the
subject has never been diagnosed with chronic obstructive pulmonary disease;

- Has a history of severe obstructive sleep apnea (OSA), with severe obstructive sleep
apnea defined as having an apnea-hypopnea index (AHI) > 30 on prior polysomnograph
(PSG). Polysomnograph is not required if there is no history of obstructive sleep
apnea;

- Is concurrently using other central nervous system (CNS) depressants, including
alcohol, except that one alcoholic drink per day will be allowed for those with
normal hepatic function provided the drink is consumed at least 2 hours prior to or
8 hours after taking the study drug. Medical marijuana is allowed if consumed at the
patient's usual dose at least 2 hours prior to or 8 hours after taking the study
drug. Recreational marijuana is not allowed from screening until end of study;

- Has evidence at screening of severe hepatic impairment as defined by a Child-Pugh
score > 10;

- Cognitive impairment that in the opinion of the investigator would prevent
completion of study procedures or the ability to provide informed consent;

- Suicidality or severe depression as measured by screening Beck Depression Inventory
II (BDI) score > 28 or score of >1 on Beck Depression Inventory II Question 9
(suicidality screen) at any time during the study;

- Any other serious and/or unstable medical condition.



Age minimum: 18 Years
Age maximum: 75 Years
Gender: All
Health Condition(s) or Problem(s) studied
Insomnia
Fatigue
Multiple Sclerosis
Intervention(s)
Drug: Suvorexant
Drug: Placebo
Primary Outcome(s)
Change in Insomnia Severity Index (ISI) Score [Time Frame: Change from Baseline to 2 Weeks]
Secondary Outcome(s)
Patient Global Impression of Change [Time Frame: Change from Baseline to 2 Weeks]
Fatigue Visual Analog Scale [Time Frame: Change from Baseline to 2 Weeks]
Change in Modified Fatigue Index Scale (MFIS) Score [Time Frame: Change from Baseline to 2 Weeks]
Secondary ID(s)
TRB 2017.2
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Merck Sharp & Dohme LLC
Ethics review
Results
Results available: Yes
Date Posted: 03/02/2025
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT03110315
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey